Stockreport

Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF data from its ongoing Phase Ia/Ib trial of NX-5948, a BTK degrader designed to treat relapsed/refractory Waldenstrom's macroglobulinaemia (WM). The findings were share [Read more]